Citation Impact
Citing Papers
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
2010 StandoutNobel
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
Risk Factors for Venous Thromboembolism
2003 Standout
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
2005 StandoutScience
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
2008
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
2002 Standout
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Ethoxyfagaronine, a synthetic analogue of fagaronine that inhibits vascular endothelial growth factor-1, as a new anti-angiogeneic agent
2014 StandoutNobel
Angiogenic inhibitors: a new therapeutic strategy in oncology
2005
Feasibility of Exercise During Treatment for Multiple Myeloma
2003
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Clinical translation of angiogenesis inhibitors
2002 Standout
Clinical Course of Patients With Relapsed Multiple Myeloma
2004
Contribution of platelets to tumour metastasis
2011 Standout
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation
2005
Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells
1999 Standout
BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma
2010
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
2003
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma
2007
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2014 Standout
Multiple Myeloma
2004
Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma
2003
Hypoxia‐inducible factor 1 and cancer pathogenesis
2008 StandoutNobel
Multiple myeloma
2000 Standout
Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
2002 Standout
Prevention of VTE in Nonsurgical Patients
2012 Standout
A structure-based computational workflow to predict liability and binding modes of small molecules to hERG
2020 StandoutNobel
Clinical trials with anti-angiogenic agents in hematological malignancies
2010
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
2003
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
2006
A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma
2006
Immunity, Inflammation, and Cancer
2010 Standout
Causes and consequences of microRNA dysregulation in cancer
2009 Standout
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
2006
Prevention of Venous Thromboembolism
2004 Standout
Hematopoietic Stem-Cell Transplantation
2006 Standout
pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels
2014 Standout
Treatment of Relapsed/Refractory Multiple Myeloma
2009
The use of novel agents in the treatment of relapsed and refractory multiple myeloma
2009
Role of liposomal anthracyclines in the treatment of multiple myeloma
2004
Thalidomide in the Treatment of Relapsed Multiple Myeloma
2000
Thrombosis and cancer
2012
Metastasis to bone: causes, consequences and therapeutic opportunities
2002 Standout
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
2003 Standout
Thalidomide
2004
Prevention of Venous Thromboembolism
2008 Standout
Multiple myeloma: evolving genetic events and host interactions
2002
Applications of machine learning in drug discovery and development
2019 Standout
Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents
2009
Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?
2006
Defining the Intensity of Conditioning Regimens: Working Definitions
2009 Standout
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2020 Standout
Proteasome Inhibitors with Photocontrolled Activity
2014 StandoutNobel
Cancer-related inflammation and treatment effectiveness
2014 Standout
High-Dose Treatment With Autologous Stem Cell Transplantation in Multiple Myeloma: Past, Present, and Future
2007
Treatment of Multiple Myeloma: A Comprehensive Review
2009
Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations
2006
NF-κB as a Therapeutic Target in Multiple Myeloma
2002
Angiogenesis as a therapeutic target
2005 StandoutNature
Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma
2002
Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene.
2001
Clinacanthus nutansExtracts Are Antioxidant with Antiproliferative Effect on Cultured Human Cancer Cell Lines
2013 Standout
Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity
2017 StandoutNobel
American College of Sports Medicine Roundtable on Exercise Guidelines for Cancer Survivors
2010 Standout
Thalidomide and thrombosis
2007
ICRP PUBLICATION 118: ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs — Threshold Doses for Tissue Reactions in a Radiation Protection Context
2012 Standout
Thromboembolism in Patients on Thalidomide for Myeloma
2002
The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development
2011
Dissemination and publication of research findings: an updated review of related biases
2010 Standout
Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group
2005
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
2010
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
2001
Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study
2007
Thalidomide Pharmacokinetics and Metabolite Formation in Mice, Rabbits, and Multiple Myeloma Patients
2004
MicroRNAs in Cancer
2009 Standout
Improved survival in multiple myeloma and the impact of novel therapies
2007 Standout
Antiangiogenesis beyond VEGF inhibition: A journey from antiangiogenic single-target to broad-spectrum agents
2013
The molecular classification of multiple myeloma
2006
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
2003
Proteasome Inhibition Alleviates SNARE-Dependent Neurodegeneration
2012 StandoutNobel
Thalidomide in multiple myeloma
2005
Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions
2005
Genetics and Cytogenetics of Multiple Myeloma
2004
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
2002
The Epidemiology of Venous Thromboembolism
2003 Standout
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
2005 Standout
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
2006 Standout
Vascular Endothelial Growth Factor-Related Pathways in Hemato-Lymphoid Malignancies
2010
High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe
2005
Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321
2006
Multiple Myeloma
2011 Standout
Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003
2007
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
2002 Standout
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group.
2000
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
2006
Works of Dan Spoon being referenced
Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone
2000
Infection – an underappreciated cause of bone pain in multiple myeloma
2003
Predicting long‐term (≥ 5 years) event‐free survival in multiple myeloma patients following planned tandem autotransplants
2002
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
2001
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
1999
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities
2000
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities
2000
Age Is Not a Prognostic Variable With Autotransplants for Multiple Myeloma
1999